Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIO-GRAIL interval prolongation of biologics in severe asthma
NL-OMON61210Phase 4Not yet recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Mar 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of mepolizumab, reslizumab, benralizumab, dupilumab and tezepelumab in severe asthma (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: Maintained asthma control after approximately 1 year with at least one step of interval prolongation. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
03
Conditions
severe asthma
Beyond the preview
Go deeper on NL-OMON61210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61210.